Home » health plans

New Hope for Type 1 Diabetes: Low-Dose Immunosuppressant Shows Promise in Preserving Beta Cells

Brussels, Belgium – In a potential breakthrough for the millions living with Type 1 diabetes, recent findings presented at the 2025 European Association for the Study of Diabetes (EASD) Meeting indicate that a low dose of anti-thymocyte globulin A (ATG) may significantly preserve beta cell function in individuals newly diagnosed with the autoimmune disease. This represents a major step forward in the ongoing quest to slow or halt the progression of Type 1 diabetes and reduce reliance on lifelong insulin therapy.

Understanding Type 1 Diabetes and the Role of beta Cells

Type 1 diabetes is a chronic autoimmune condition affecting an estimated 9.5 million people globally, including roughly 2 million in the United States. The disease occurs when the body’s immune system mistakenly attacks and destroys the insulin-producing beta cells located in the pancreatic islets.Without sufficient insulin, the body cannot effectively regulate blood glucose levels, leading to serious health complications. Currently, management relies heavily on exogenous insulin governance and constant blood sugar monitoring.

How ATG Works as an Immunosuppressant

Anti-thymocyte globulin A (ATG) is an immunosuppressant traditionally employed to prevent organ rejection following transplantation. It functions by selectively depleting certain immune cells that contribute to the destructive autoimmune response. While higher doses of ATG are used in transplant medicine, researchers have been exploring the potential of lower doses to modulate the immune system in Type 1 diabetes without causing excessive immunosuppression.

the MELD-ATG Trial: A Closer Look

The phase 2 MELD-ATG study, a collaborative effort involving INNODIA, Breakthrough T1D, the Helmsley Charitable Trust, and the European Commission’s Innovative Medicines Initiative, enrolled 114 patients aged 5 to 25 years. The innovative trial design involved testing multiple ATG doses-0.5 mg/kg and 2.5 mg/kg-alongside a placebo. The medication was administered intravenously over two consecutive days, and the results showed a clear advantage with the lower dose.

Key Findings: Lower Dose, Fewer Side Effects, Better Outcomes

Researchers discovered that the 0.5 mg/kg dose of ATG was not only well-tolerated by participants but also demonstrated meaningful clinical benefits.Patients receiving the lower dose exhibited substantially higher C-peptide levels, a key indicator of the body’s own insulin production, compared to those in the placebo group. This improvement in insulin production correlated with lower hemoglobin A1c levels, signifying improved blood glucose control. This data suggests the lowest dose needed to preserve beta cells in new T1D patients with the fewest side effects.

ATG Dose (mg/kg) C-Peptide Levels HbA1c Levels Side Effects
0.5 Higher than placebo Lower than Placebo Minimal
2.5 Moderate Increase Moderate Decrease More Common
placebo Lowest Highest None

Did You No? Type 1 diabetes is not caused by diet or lifestyle but is an autoimmune disease with complex genetic and environmental factors.

Chantal Mathieu, MD, Ph.D., a professor of Medicine at Catholic University Leuven in Belgium, presented these encouraging findings at the EASD meeting.Breakthrough T1D officials have hailed the results as a pivotal moment, highlighting the identification of an optimal ATG dosage that maximizes beta cell preservation while minimizing adverse effects.

Pro Tip: Early diagnosis and intervention are vital in managing Type 1 diabetes. Consult with a healthcare professional for annual screenings if you have a family history of the condition.

The future of Type 1 Diabetes Treatment

while insulin therapy remains the cornerstone of Type 1 diabetes management, ongoing research seeks to delay disease progression and potentially restore beta cell function. Beyond ATG, therapies targeting the immune system, such as immunomodulatory drugs and vaccines, are under inquiry. The advancement of artificial pancreas systems, which automate insulin delivery, also offers a promising avenue for improving quality of life for individuals with Type 1 diabetes.

The prevalence of Type 1 diabetes is projected to rise in the coming decades, underscoring the urgent need for innovative treatment strategies. The continued exploration of immune-modulating therapies like ATG, coupled with advancements in diabetes technology, provides a beacon of hope for those affected by this chronic condition.

Frequently Asked Questions About ATG and Type 1 Diabetes

  • What is ATG and how does it relate to Type 1 diabetes? ATG is an immunosuppressant being investigated for its potential to preserve beta cell function in individuals newly diagnosed with Type 1 diabetes.
  • What are the potential side effects of ATG treatment? While higher doses of ATG can cause significant side effects,the lower dose tested in the MELD-ATG study was generally well-tolerated with minimal adverse effects.
  • Is ATG a cure for Type 1 diabetes? No, ATG is not a cure. Though,it may help delay disease progression and reduce the need for high doses of insulin.
  • Who is eligible for ATG treatment for Type 1 diabetes? Currently, ATG is being studied in newly diagnosed patients and is not yet a standard treatment.
  • How does the MELD-ATG study contribute to our understanding of Type 1 diabetes? It has identified an optimal, low dose of ATG that balances efficacy with safety, paving the way for potential future therapeutic interventions.

What are your thoughts on this new research? Do you believe this could significantly impact the lives of those with type 1 diabetes? share your comments below!

What are the potential benefits of developing more selective ATG preparations that spare Tregs while depleting effector T cells?

ATG Mitigates Organ Rejection and Protects Insulin-Producing Beta Cells in Transplant Research

Understanding the Challenge of Organ Rejection

Organ transplantation offers a life-saving treatment for individuals wiht end-stage organ failure.However, a significant hurdle remains: organ rejection. This occurs when the recipient’s immune system identifies the transplanted organ as foreign and mounts an attack. The immune response primarily targets the donor’s human leukocyte antigens (hlas), triggering a cascade of events leading to graft damage and potential failure. Immunosuppression is crucial, but traditional methods often come with significant side effects. Transplant rejection rates, while improving, still necessitate ongoing research into more targeted and effective therapies.Graft survival is directly linked to minimizing this immune response.

ATG: A Powerful Immunomodulatory Agent

Antithymocyte globulin (ATG) is a polyclonal antibody derived from animals (typically rabbits or horses) immunized with human thymocytes.It’s a potent immunomodulatory agent used in transplantation to prevent and treat acute rejection. Unlike broad-spectrum immunosuppressants, ATG selectively depletes T lymphocytes – the key players in the rejection process.

Here’s how ATG works:

* T-cell Depletion: ATG binds to various surface molecules on T cells, leading to thier removal from circulation. This includes both CD4+ helper T cells and CD8+ cytotoxic T cells.

* Immunomodulation: Beyond depletion, ATG modulates the remaining immune cells, reducing their activation and effector functions. This includes impacting cytokine production and reducing antibody-mediated rejection risk.

* Regulatory T Cell Sparing: Interestingly, some ATG preparations demonstrate a degree of sparing for regulatory T cells (Tregs), which are crucial for maintaining immune tolerance. This is a key area of ongoing research.

ATG and Beta Cell Protection in Islet Transplantation

Islet transplantation holds immense promise for individuals with Type 1 Diabetes. However, beta cell rejection remains a major obstacle. Beta cells, responsible for insulin production, are particularly vulnerable to immune attack. ATG has shown remarkable efficacy in protecting these fragile cells.

* Improving Islet Graft Survival: Studies demonstrate that ATG induction therapy substantially improves islet graft survival rates. By suppressing the initial immune response, ATG allows the transplanted islets to establish themselves and begin functioning.

* Reducing Insulin Dependence: Successful islet transplantation, facilitated by ATG, can lead to reduced or even eliminated insulin dependence in recipients.

* Mechanisms of Beta Cell Protection: ATG’s protective effects extend beyond simple T-cell depletion. It appears to:

* Reduce inflammation around the islet graft.

* Promote the progress of immune tolerance.

* Protect beta cells from direct cytotoxic attack.

ATG Protocols in Transplantation: Current Practices

The use of ATG varies depending on the type of transplant and the recipient’s risk profile. Common protocols include:

  1. induction Therapy: ATG is frequently enough administered as part of an induction regimen promptly after transplantation. This aims to provide intense immunosuppression during the initial, most vulnerable period.
  2. Treatment of Acute Rejection: ATG is also used to treat established acute rejection episodes. In these cases, higher doses might potentially be required to reverse the rejection process.
  3. Dosage and Administration: ATG is typically administered intravenously over several days. Dosage is adjusted based on body weight and the specific ATG product used.
  4. Combination Therapy: ATG is almost always used in combination with other immunosuppressants, such as calcineurin inhibitors (tacrolimus, cyclosporine) and mycophenolate mofetil.This synergistic approach maximizes efficacy while minimizing side effects.

Potential side Effects and Management

While highly effective, ATG is not without potential side effects. These can include:

* Infusion Reactions: Fever, chills, rash, and hypotension are common during ATG infusions. Pre-medication with corticosteroids and antihistamines can help mitigate these reactions.

* cytokine Release Syndrome (CRS): A more serious complication, CRS is caused by the massive release of cytokines following T-cell depletion. Symptoms can include fever, respiratory distress, and neurological changes.

* Infections: ATG-induced immunosuppression increases the risk of opportunistic infections. Prophylactic antibiotics and antiviral medications are often prescribed.

* Serum Sickness: A delayed hypersensitivity reaction characterized by fever, rash, and joint pain.

Careful monitoring and prompt management of side effects are crucial for ensuring patient safety.

Future Directions in ATG Research

Ongoing research is focused on:

* Developing more selective ATG preparations: Aiming to spare Tregs while effectively depleting effector T cells.

* Personalized ATG dosing: Tailoring ATG dosage based on individual patient characteristics and immune profiles.

* Combining ATG with novel immunomodulatory therapies: Exploring synergistic combinations to enhance efficacy and reduce side effects.

* Long-term impact on immune tolerance: Investigating whether ATG can promote lasting immune tolerance,

0 comments
0 FacebookTwitterPinterestEmail

Rwanda‘s Rapid Response to Marburg Virus outbreak Offers Hope for Pandemic Prevention

Kigali,Rwanda – A 2024 outbreak of the deadly Marburg virus in Rwanda’s capital city presented a critical test for the nation’s public health infrastructure. Unlike previous outbreaks across Africa, known for exceptionally high mortality rates, the Rwandan response successfully limited fatalities, offering valuable lessons for global pandemic preparedness. The World Health Organization continues to monitor the situation and emphasizes the importance of proactive measures.

The Outbreak and Early Response

The initial case emerged on August 26, 2024, when a woman was admitted to an intensive care unit in Kigali after a Cesarean delivery. She swiftly succumbed to the illness, exhibiting severe fever, unusual bleeding, and elevated liver enzyme levels within 24 hours. Epidemiological investigations revealed her husband, a miner, had been working in a bat-inhabited tunnel-a known reservoir for the Marburg virus. He displayed initial symptoms in early August but did not seek medical attention, later testing positive for antibodies.

Exposure was traced to a 37-year-old man, a diabetic patient sharing the ICU room. He seemingly contracted the virus from contaminated surfaces during his treatment. This swift identification, tho tragic in the first case, proved pivotal in containing the spread.

A ‘One Health’ Approach and Innovative Treatments

Rwanda’s accomplished containment strategy hinged upon a extensive “One Health” approach. This integrated human, animal, and environmental health considerations, fostering collaboration between community health workers, medical specialists, bat biologists, and conservationists. Early case identification, coupled with aggressive supportive care, proved crucial.

Furthermore, Rwandan authorities expedited access to investigational treatments: remdesivir, previously used for COVID-19, and MBP091, a monoclonal antibody designed to target the Marburg virus. Though neither drug is officially approved for Marburg treatment, their use-approved through an expedited regulatory process-showed promise. Of the 52 patients treated with remdesivir, only 3 died, while 2 of 10 treated with MBP091 succumbed to the illness.

Vaccination Efforts

A phase 1 trial had previously demonstrated the safety of the chimpanzee adenovirus 3-vectored Marburg virus vaccine (ChAd3-MARV). Rwandan regulators authorized its use, and a phase 2 trial was initiated, vaccinating 1,710 individuals, including frontline healthcare workers and high-risk contacts, following WHO protocols.

Outbreak Statistics and Declared Victory

The Kigali outbreak comprised three distinct clusters: within the initial hospital, at a second medical facility linked to a physician involved in the first case’s resuscitation, and among the index case’s family and close contacts. A total of 66 laboratory-confirmed cases were recorded, tragically resulting in 15 fatalities, representing a case fatality rate of 23% – significantly lower than those seen in previous Marburg outbreaks.

By November 11, 2024, the last patient at the dedicated outpatient clinic was discharged, and on december 20, 2024, Rwanda officially declared the outbreak over.

Key Metric Value
Total Confirmed Cases 66
Total Fatalities 15
Case Fatality Rate 23%
People Vaccinated 1,710
Outbreak Declared Over December 20, 2024

Did You Know? The Marburg virus, like Ebola, belongs to the Filoviridae family and is known for causing severe hemorrhagic fevers.

Pro Tip: Early detection and isolation are critical in containing outbreaks of highly contagious diseases like Marburg.

Looking Ahead: Strengthening global health Security

The Rwandan experience underscores the importance of investing in robust public health systems, proactive surveillance, and rapid response capabilities. Experts emphasize the need for continued research into effective treatments and vaccines, as well as strengthened international collaboration to prevent and control future outbreaks of Marburg and other emerging infectious diseases. The United States Centers for Disease Control and Prevention (CDC) provides detailed facts on Marburg virus disease.

Frequently Asked Questions About Marburg Virus


What are yoru thoughts on the importance of international collaboration in fighting emerging infectious diseases? Share your comments below, and don’t forget to share this article with your network!

What specific diagnostic tests were utilized in Rwanda to identify Marburg virus infection?

RwandaS Marburg Virus Outbreak: swift Response prevents Further Escalation

Understanding the Marburg Virus & Initial Outbreak in Rwanda

The recent outbreak of Marburg virus disease (MVD) in rwanda,declared in August 2024,highlighted the critical importance of rapid public health responses. Marburg, a highly virulent viral hemorrhagic fever, is closely related to Ebola. The initial case, confirmed in a 34-year-old male in the nyabihu District, triggered immediate action from the Rwandan Ministry of Health and the World Health Institution (WHO). Early detection and swift containment measures were pivotal in preventing a widespread epidemic. Viral hemorrhagic fevers are a significant global health concern, demanding constant vigilance.

Rapid Response strategies Employed by Rwanda

Rwanda’s success in controlling the outbreak stemmed from a multi-pronged approach, building on lessons learned from previous disease outbreaks, including the COVID-19 pandemic. Key strategies included:

* Immediate isolation & Contact Tracing: The index case was quickly isolated, and a robust contact tracing system was initiated. This involved identifying all individuals who had come into contact with the confirmed case, monitoring them for symptoms, and providing appropriate care. Contact tracing is a cornerstone of outbreak control.

* Enhanced Surveillance: The Ministry of Health significantly increased surveillance efforts across the country, focusing on identifying potential new cases and clusters. This included strengthening laboratory capacity for rapid diagnosis of Marburg virus infection.

* Risk Dialogue & Community Engagement: A comprehensive risk communication campaign was launched to educate the public about Marburg virus, its symptoms, modes of transmission, and preventive measures. This involved utilizing various channels, including radio, television, social media, and community health workers. Public health education is vital for behavioral change.

* Safe Burial Practices: Safe and dignified burial practices were implemented to prevent further transmission of the virus. This involved training burial teams in proper infection prevention and control measures.

* Support from International Partners: The WHO, the Africa Centres for Disease Control and Prevention (Africa CDC), and other international partners provided technical and logistical support to Rwanda, including personnel, equipment, and funding.

Key Symptoms & Transmission of Marburg Virus

Recognizing the symptoms of Marburg virus is crucial for early diagnosis and treatment. Initial symptoms can be subtle and often mimic other febrile illnesses. However,as the disease progresses,more severe symptoms develop:

* Early Symptoms (5-10 days post-exposure): Fever,severe headache,muscle aches,weakness.

* Later Symptoms: Watery diarrhea, vomiting, abdominal pain, unexplained bleeding (hemorrhage) from various orifices (eyes, nose, gums, rectum).

* Severe Symptoms: Organ failure, shock, and possibly death.

Transmission occurs through:

* Direct contact with the bodily fluids (blood, urine, saliva, vomit, feces) of infected people.

* Contact with surfaces contaminated with these fluids.

* contact with infected animals, especially fruit bats, which are considered the natural reservoir of the virus.

* burial ceremonies involving direct contact with the body of a deceased infected individual.

Laboratory Confirmation & Diagnostic Techniques

Rapid and accurate laboratory diagnosis is essential for confirming Marburg virus cases and initiating appropriate treatment. The primary diagnostic methods include:

* Polymerase Chain Reaction (PCR): PCR tests detect the presence of the virus’s genetic material in samples (blood,urine,saliva).This is the most common and reliable method.

* antigen Detection tests: These tests identify specific viral proteins in samples.

* Antibody Detection Tests: These tests detect antibodies produced by the body in response to the virus. Useful for confirming past infection.

* Virus Isolation: Growing the virus in cell culture, though more complex and time-consuming, provides definitive confirmation.

rwanda leveraged its existing laboratory infrastructure, bolstered by support from the WHO and Africa CDC, to ensure timely and accurate diagnostic testing. Laboratory capacity building is a critical investment in pandemic preparedness.

The Role of Vaccination & Potential Treatments

currently, there is no licensed vaccine specifically for Marburg virus. However, a candidate vaccine, developed by the Sabin Vaccine Institute, has shown promising results in clinical trials and was deployed under compassionate use during the outbreak. The Marburg vaccine is still under evaluation, but represents a significant step forward in preventing future outbreaks.

Treatment for Marburg virus is primarily supportive, focusing on managing symptoms and preventing complications. This includes:

* fluid and electrolyte replacement: To combat dehydration caused by diarrhea and vomiting.

* Blood transfusions:

0 comments
0 FacebookTwitterPinterestEmail

São Paulo Court Reverses Precedents on Health Plan Coverage

Published: September 19, 2025 at 10:00 AM PDT

The Tribunal of Justice of São Paulo (TJ/SP) has overturned previous rulings concerning health plan regulations, impacting consumer rights and insurer obligations. This decision follows a formal request and internal review highlighting inconsistencies with broader legal interpretations established by the Superior Court of Justice (STJ).

Key Changes to Health Plan regulations

Last Wednesday, September 10, the Special Body of the TJ/SP revoked precedents 100 and 102, which had previously guided decisions related to health insurance contracts. The move came after a letter from Judge Heraldo de Oliveira Silva, President of the Private Law Section, initiated a reevaluation process.

The Special Class of Private Law I determined that the existing precedents diverged from established guidance by the STJ, necessitating a correction to ensure legal consistency across the state.

The revoked Precedent 100: Consumer Protection Code Request

Previously,Precedent 100 stipulated that health plan contracts were subject to the regulations of the Consumer Protection Code (CDC) and Law 9.656/98,nonetheless of when the agreement was initially established. This meant even older contracts benefited from modern consumer protections. Now, this retroactive application is no longer binding within the TJ/SP framework.

Did You Know? The Consumer Protection code in Brazil is a crucial piece of legislation designed to protect consumers from unfair practices and ensure transparency in commercial transactions.

The Revoked precedent 102: Coverage for Experimental Treatments

Precedent 102 had previously mandated that health plans could not deny coverage for medically indicated treatments solely on the grounds of their experimental nature or absence from the National Health Agency (ANS) list of approved procedures. This ruling aimed to ensure patients had access to potentially life-saving treatments, even if not yet fully standardized.

With this reversal, the obligation to cover experimental treatments, even with medical justification, is no longer automatically enforced in TJ/SP rulings.

Here’s a swift comparison of the rulings:

Precedent Previous Ruling Current Status
100 CDC & Law 9.656/98 applied retroactively to health plans. No longer binding; retroactive application not guaranteed.
102 Denial of coverage for medically indicated experimental treatments was abusive. No longer binding; coverage not automatically required.

Understanding Health Plan Regulations in Brazil

Health plan regulations in Brazil are complex and constantly evolving. The ANS (Agência Nacional de Saúde Suplementar) plays a vital role in overseeing and regulating the private health insurance sector. Recent data from the ANS, published in June 2024, indicates that over 48 million Brazilians are covered by private health plans, representing approximately 23% of the population. ANS Official Website

Consumers should carefully review their health plan contracts, understanding the scope of coverage, exclusions, and procedures for filing claims. Pro Tip: Always keep a copy of your health plan contract and any related documentation readily accessible.

Changes in jurisprudence, like the one enacted by the TJ/SP, highlight the importance of staying informed about legal developments affecting consumer rights.

What impact do you think this decision will have on access to healthcare for Brazilian citizens? How should health plans balance cost control with the need to provide innovative treatments?

Frequently Asked Questions about Health Plan Coverage


Share this article and let us know your thoughts in the comments below!


What specific documentation is now considered crucial when seeking coverage for off-label medications following the TJ/SP ruling?

TJ/SP Annuls Two Precedents on Health Plans: Key Changes and Implications Unveiled

Understanding the Landmark Decision

the Tribunal de Justiça de São Paulo (TJ/SP) recently delivered a meaningful ruling, annulling two long-standing precedents concerning health plan coverage. This decision impacts millions of Brazilians relying on planos de saúde (health plans) and introduces crucial changes to how disputes regarding coverage are handled. The core of the matter revolves around the interpretation of ANS (agência Nacional de Saúde Suplementar) regulations and the extent of judicial intervention in contractual agreements between patients and health insurance providers. This article breaks down the key changes and their implications for patients, health plans, and legal professionals.

Precedents Overturned: A Detailed Look

The two precedents annulled by the TJ/SP were:

  1. Mandatory Coverage of Off-Label Medications: Previously, the TJ/SP consistently ruled in favor of patients seeking coverage for medications not officially approved by ANVISA (Agência Nacional de Vigilância Sanitária) – known as “off-label” use – if supported by medical evidence.This precedent has now been overturned. The court now emphasizes that ANVISA’s approval is a critical factor in determining coverage eligibility.
  2. Automatic Judicial Substitution of Treatment Plans: The second precedent allowed patients to directly request a judge to substitute a health plan’s proposed treatment plan with an alternative recommended by their physician, even if the plan adhered to ANS guidelines. This has also been reversed, with the court now prioritizing the health plan’s adherence to established protocols and ANS resolutions.

Implications for Patients seeking Healthcare Coverage

These changes significantly impact patients’ access to healthcare and their ability to challenge health plan decisions.

* Increased Reliance on ANVISA Approval: Patients now face a higher hurdle in securing coverage for off-label medications. Demonstrating compelling medical justification and the absence of ANVISA-approved alternatives will be crucial. This impacts treatments for rare diseases and personalized medicine approaches.

* Strengthened Health Plan Authority: Health plans now have greater latitude in determining treatment protocols. Patients will need to exhaust administrative appeals within the health plan before seeking judicial intervention.

* Focus on ANS Normative Resolutions: The TJ/SP’s decision reinforces the importance of ANS Normative resolutions (resoluções normativas) as the primary framework for evaluating health plan coverage.Understanding these resolutions is now more critical than ever for both patients and legal counsel.

* Potential for Increased Litigation Costs: While judicial intervention is now more restricted,complex cases involving novel treatments or disputes over ANS interpretations are likely to continue,potentially increasing litigation costs for patients.

What This Means for Health plans & Operadoras de Saúde

The ruling provides health plans with increased legal certainty and reduces the risk of unfavorable court decisions.

* Reduced Financial Exposure: By limiting the obligation to cover off-label medications and respecting ANS-compliant treatment plans, health plans can expect to reduce their financial exposure to legal claims.

* Enhanced Contractual Control: The decision reinforces the validity of contractual agreements between health plans and their members, allowing operadoras de saúde (health operators) to maintain greater control over coverage decisions.

* Importance of Compliance: Maintaining strict compliance with ANS regulations is now paramount. Health plans must ensure their internal protocols align with the latest Normative Resolutions to minimize legal challenges.

* Proactive Communication with Members: Clear and clear communication with members regarding coverage policies and ANS guidelines will be essential to manage expectations and prevent disputes.

Navigating the New Landscape: Practical Tips

For patients and their advocates:

  1. Prioritize Administrative Appeals: Thoroughly exhaust all administrative appeal processes within the health plan before considering legal action.
  2. Gather Comprehensive Medical Documentation: If seeking coverage for off-label medications,compile robust medical evidence demonstrating the treatment’s necessity and lack of viable alternatives.
  3. Understand ANS Resolutions: Familiarize yourself with relevant ANS Normative Resolutions pertaining to yoru specific health plan and medical condition.
  4. Seek Legal Counsel: Consult with a lawyer specializing in health plan law to assess your options and navigate the legal complexities.

For health plans:

  1. Review and Update Internal Protocols: Ensure all internal protocols align with the latest TJ/SP ruling and ANS regulations.
  2. Invest in Compliance Training: Provide comprehensive training to staff on ANS compliance and
0 comments
0 FacebookTwitterPinterestEmail
Newer Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.